Sign in
Not yet taking people in HungaryPhase 2/3

Checks plaque changes in heart arteries after short statin treatment

Tests whether short statin treatment changes plaque in heart arteries in adults with chest pain.

Key facts

Who runs it
Semmelweis University
Where
Budapest VIII, HungarySee the site
Trial code
Registry title
Changes in plaque characteristics after short-term statin therapy assessed with coronary CT (INTENSE)
Status
Not yet recruiting
Phase
Phase 2/3
People taking part
140 people, planned
Started
1 Jul 2025
Expected to end
31 Dec 2029
Type of study
Interventional
Record updated
26 September 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with stable chest pain who are having a coronary CT scan and have never taken statins. It follows plaque changes over 3 months.

Age
Women 45-75 years; men 40-75 years.
Sex
Women and men can join.
Disease stage
Coronary artery disease with at least one partially-calcified or non-calcified plaque; FFRCT>0.75 distal to the stenosis.
Earlier treatment
Must never have had statin or other lipid-lowering treatment (such as ezetimibe).
Biomarker or test result
FFRCT>0.75 distal to the stenosis.

Main reasons for not taking part

  • Diabetes (type I or II)
  • Coronary stent or bypass graft, or previous heart attack
  • Acute liver disease, or ALT or creatine kinase more than 3x upper limit of normal
  • Pregnancy or breastfeeding
  • Chronic renal failure or eGFR <30 ml/m2

The registry criteria, word for word

Show all 26 criteriaShow less

Who can take part

  • Clinically indicated coronary CT angiography
  • 45-75 yo. females or min. 40-75 yo. males
  • Statin naive patients
  • There are no contraindications to CT angiography
  • Understanding and signing the consent form
  • At least one partially-calcified or non-calcified plaque
  • FFRCT>0.75 distal to stenosis

Who cannot take part

  • Previous myocardial infarction
  • Concomitant treatment with the sofosbuvir/velpatasvir/voxilaprevir combination
  • Concomitant treatment with cyclosporine
  • History of statin or other lipid lowering (ezetimibe) treatment
  • Diabetes mellitus (Type I. and II.)
  • Acute liver disease
  • Hypersensitivity to any of the excipients of the investigational medicinal product
  • Elevated low density lipoprotein (>5 mmol/L)
  • Chronic renal failure or decreased renal function (eGFR <30 ml/m2)
  • FFRCT<0.75 distal to stenosis
  • females below 45 yo. or males below 40 yo
  • Coronary artery stent or bypass graft
  • Women of childbearing potential who are not using an adequate method of contraception
  • Elevated alanine aminotransferase levels (>3x upper limit of normal)
  • Elevated creatine kinase (>3x upper limit of normal)
  • Pregnancy or breastfeeding
  • >75 yo. patients (both genders)
  • Active oncological treatment
  • ≥70% luminal stenosis in proximal LAD or ≥50% luminal stenosis in left main coronary artery

Where in Hungary

  • Semmelweis UniversityBudapest VIII, HungaryNot yet recruiting

About the trial

What the trial wants to find out

Change in non-calcified plaque volume during a 3-month follow-up period.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Changes in plaque characteristics after short-term statin therapy assessed with coronary CT
Plain-language title
Checks plaque changes in heart arteries after short statin treatmentGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
26 September 2025